Gibco™ Express Five™ SFM

上海金畔生物科技有限公司提供Gibco™ Express Five™ SFM ,欢迎访问官网了解更多产品信息和订购。
Gibco™ Express Five™ SFM

详情介绍

Gibco™ Express Five™ SFM

This medium requires the addition of 16 mM L-glutamine before use. Gibco™ Express Five™ SFM features:


• Superior long-term suspension growth of High Five™ cells

• Protein-free, serum-free formulation

• Optimized for recombinant protein production

• Scalable in the CelliGen™ bioreactor and WAVE Bioreactor™ System


Superior growth of High Five™ cells:

Gibco™ Express Five™ SFM provides peak cell densities of up to 6 × 106 viable cells per mL in shaker cultures. Cells adapted to other commercially available serum-free media can be subcultured directly into Gibco™ Express Five™ SFM, usually without any further adaptation (see figure). Cells usually require adaptation from serum-containing formulations.


Protein-free, serum-free formulation:

Gibco™ Express Five™ SFM is a protein-free and serum-free formulation, allowing for easier purification of your protein of interest.


Optimized for recombinant protein expression:

Gibco™ Express Five™ SFM is optimized for high protein production using the Baculovirus Expression Vector System (BEVS). Using BEVS, we routinely achieve rβ-galactosidase protein expression of up to 1.7 U/cell, a significant improvement over other media (see figure)


Scalable in the CelliGen™ bioreactor and WAVE Bioreactor™ System:

Protein production using Gibco™ Express Five™ SFM can be scaled up in bioreactors such as the 5 L CelliGen™ bioreactor and the WAVE Bioreactor™ System. The appropriate impeller or rocking speed and seeding density should be optimized for each system. Depending on the bioreactor design, it may be necessary to supplement Gibco™ Express Five™ SFM with additional Pluronic™ F-68 to avoid sheer stress in the culture.


cGMP manufacturing and quality system:

Gibco™ Express Five™ SFM is manufactured at a cGMP-compliant facility located in Grand Island, New York. The facility is registered with the FDA as a medical device manufacturer and is certified to ISO 13485 standards.

Gibco™ CTS™ AIM V™ SFM (RUO)

上海金畔生物科技有限公司提供Gibco™ CTS™ AIM V™ SFM (RUO) ,欢迎访问官网了解更多产品信息和订购。
Gibco™ CTS™ AIM V™ SFM (RUO)

详情介绍

Gibco™ CTS™ AIM V™ SFM (RUO)

Features include:

• Used as ancillary reagent in Provenge™ (sipuleucel-T), the first therapeutic cancer vaccine approved by the FDA [1]

• Accommodates multiple culture formats, including culture flasks, WAVE bags, and G-Rex devices

• Supports T-cell activation using Dynabeads magnetic beads and stimulatory antibody- and antigen-presenting cell protocols

• Supports expansion of gene-modified CAR T cells (lentiviral transduction)

• Manufactured in conformity with cGMP for medical devices


Proven use:

CTS AIM V SFM for research use only is based on the same formulation as our therapeutic-grade CTS AIM V SFM, which was the first FDA-cleared, therapeutic-grade, commercial SFM in the U.S. used in adoptive immunotherapy applications. CTS AIM V SFM is used as an ancillary reagent in Provenge™ (sipuleucel-T), the first therapeutic cancer vaccine approved by the FDA.


GMP manufactured:

The primary manufacturing site for CTS AIM V SFM is FDA-registered and has an ISO13485-certified quality management system. The methods and controls used for the manufacturing are in conformity with current Good Manufacturing Practices for medical devices, 21 CFR Part 820. Alternate manufacturing sites are available, providing risk mitigation by helping to ensure security of supply.


Versatility:

CTS AIM V SFM has been widely adopted in clinical research applications including the culture of CAR T, polyclonal T, natural killer, dendritic, and TIL cells. CTS AIM V SFM accommodates multiple culture formats, including culture flasks, WAVE™ bags, and G-Rex™ devices. CTS AIM V SFM was designed to support expansion of cultured human immune cells when supplemented with either human AB serum or CTS Immune Cell SR.


What you get:

CTS AIM V SFM is available in a 1-liter bottle for small volume users as well as a 10-liter bag for larger volume users. Full traceability documentation such as Certificate of Origin, Certificate of Analysis, and Drug Master File are available.


1. Madan RA, Gulley JL. Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Expert Rev Vaccines. 2011 Feb;10(2):141-50.

Gibco™ OptiPRO™ SFM

上海金畔生物科技有限公司提供Gibco™ OptiPRO™ SFM ,欢迎访问官网了解更多产品信息和订购。
Gibco™ OptiPRO™ SFM

详情介绍

Gibco™ OptiPRO™ SFM

In addition, OptiPRO™ SFM has successfully grown other cell lines, such as Hela, BHK-21 and COS-7. Gibco™ OptiPRO™ SFM features:

• Serum-free, animal origin-free, low protein formulation

• Direct adaptation for many popular cell lines


Serum-free, animal origin-free, low protein formulation:

Gibco™ OptiPRO™ SFM is formulated with a very low protein concentration (< 10 µg/ml), allowing for easier purification of your recombinant protein.


Direct adaptation for many popular cell lines:

Gibco™ OptiPRO™ SFM has been designed for growth of kidney-derived cell lines such as MDCK, MDBK, VERO and PK-15. In addition, OptiPRO™ SFM has successfully grown other cell lines, such as Hela, BHK-21 and COS-7, allowing you to choose a single medium for multiple cell lines.


Product Use:

For Research Use Only. Not for use in diagnostic procedures.


cGMP Manufacturing and Quality System:

Gibco™ OptiPRO™ SFM is manufactured at a cGMP compliant facility located in Grand Island, New York. The facility is registered with the FDA as a medical device manufacturer and is certified to ISO 13485 standards.